Agniswamy Johnson, Fang Bin, Weber Irene T
Department of Biology, Molecular Basis of Disease, Georgia State University, Atlanta, GA 30302, USA.
FEBS J. 2007 Sep;274(18):4752-65. doi: 10.1111/j.1742-4658.2007.05994.x. Epub 2007 Aug 14.
Many protein substrates of caspases are cleaved at noncanonical sites in comparison to the recognition motifs reported for the three caspase subgroups. To provide insight into the specificity and aid in the design of drugs to control cell death, crystal structures of caspase-7 were determined in complexes with six peptide analogs (Ac-DMQD-Cho, Ac-DQMD-Cho, Ac-DNLD-Cho, Ac-IEPD-Cho, Ac-ESMD-Cho, Ac-WEHD-Cho) that span the major recognition motifs of the three subgroups. The crystal structures show that the S2 pocket of caspase-7 can accommodate diverse residues. Glu is not required at the P3 position because Ac-DMQD-Cho, Ac-DQMD-Cho and Ac-DNLD-Cho with varied P3 residues are almost as potent as the canonical Ac-DEVD-Cho. P4 Asp was present in the better inhibitors of caspase-7. However, the S4 pocket of executioner caspase-7 has alternate regions for binding of small branched aliphatic or polar residues similar to those of initiator caspase-8. The observed plasticity of the caspase subsites agrees very well with the reported cleavage of many proteins at noncanonical sites. The results imply that factors other than the P4-P1 sequence, such as exosites, contribute to the in vivo substrate specificity of caspases. The novel peptide binding site identified on the molecular surface of the current structures is suggested to be an exosite of caspase-7. These results should be considered in the design of selective small molecule inhibitors of this pharmacologically important protease.
与已报道的三种半胱天冬酶亚组的识别基序相比,许多半胱天冬酶的蛋白质底物在非典型位点被切割。为了深入了解特异性并辅助设计控制细胞死亡的药物,我们测定了半胱天冬酶 -7 与六种肽类似物(Ac-DMQD-Cho、Ac-DQMD-Cho、Ac-DNLD-Cho、Ac-IEPD-Cho、Ac-ESMD-Cho、Ac-WEHD-Cho)形成复合物的晶体结构,这些肽类似物涵盖了三个亚组的主要识别基序。晶体结构表明,半胱天冬酶 -7 的 S2 口袋可以容纳多种残基。P3 位置不需要谷氨酸,因为具有不同 P3 残基的 Ac-DMQD-Cho、Ac-DQMD-Cho 和 Ac-DNLD-Cho 几乎与典型的 Ac-DEVD-Cho 一样有效。P4 天冬氨酸存在于更好的半胱天冬酶 -7 抑制剂中。然而,执行者半胱天冬酶 -7 的 S4 口袋有与起始半胱天冬酶 -8 类似的用于结合小的支链脂肪族或极性残基的交替区域。观察到的半胱天冬酶亚位点的可塑性与许多蛋白质在非典型位点的切割报道非常吻合。结果表明,除了 P4 - P1 序列之外的因素,如外部位点,对半胱天冬酶的体内底物特异性有贡献。在当前结构的分子表面鉴定出的新型肽结合位点被认为是半胱天冬酶 -7 的外部位点。在设计这种具有药理学重要性蛋白酶的选择性小分子抑制剂时应考虑这些结果。